| Literature DB >> 35057060 |
Catarina S Miranda1, Ana Francisca G Silva2, Sílvia M M A Pereira-Lima2, Susana P G Costa2, Natália C Homem3, Helena P Felgueiras1.
Abstract
Electrospinning and wet-spinning have been recognized as two of the most efficient and promising techniques for producing polymeric fibrous constructs for a wide range of applications, including optics, electronics, food industry and biomedical applications. They have gained considerable attention in the past few decades because of their unique features and tunable architectures that can mimic desirable biological features, responding more effectively to local demands. In this review, various fiber architectures and configurations, varying from monolayer and core-shell fibers to tri-axial, porous, multilayer, side-by-side and helical fibers, are discussed, highlighting the influence of processing parameters in the final constructs. Additionally, the envisaged biomedical purposes for the examined fiber architectures, mainly focused on drug delivery and tissue engineering applications, are explored at great length.Entities:
Keywords: drug delivery; electrospinning; fiber architectures; fibrous constructs; tissue engineering; wet-spinning
Year: 2022 PMID: 35057060 PMCID: PMC8781456 DOI: 10.3390/pharmaceutics14010164
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic representation of an electrospinning apparatus.
Figure 2Schematic representation of the most common electrospun fiber structural organizations.
Figure 3SEM micrograph of a core-shell electrospun fiber (adapted from [80], published by MDPI, 2019).
Figure 4Scanning electron microscope (SEM) micrograph of an hollow nanofiber (adapted from [80], published by MDPI, 2019).
Figure 5SEM micrograph of a porous electrospun fiber (adapted from [80], published by MDPI, 2019).
Main applications of electrospun fibers with various structural organizations and respective solution/processing parameters.
| Active Agents | |||||||
|---|---|---|---|---|---|---|---|
| Polymers | Name | Characteristics | Structural | Solution and Processing Parameters | Major Findings | Envisaged Applications | Ref. |
| PU; HA/St | HA | Group of polysaccharide molecules, usually found on connective tissues | Core-shell | Core: PU (12% | A uniform structure was obtained; modification with HA enhanced cell adhesion into fibrous scaffolds | Skin scaffolding systems; wound healing | [ |
| PCL; PEG | Ag NPs; ZnO NPs | AgNPs display unique optical, electrical, thermal, and biological properties, being used for several antimicrobial and medical-coating applications; ZnO is an essential ingredient for several enzymes, being used for pain relieve and as an antimicrobial agent. | Core-shell | Core: Ag NP (0.01/0.02% | Ag NPs showed a fine-tuned release rate through pores formed along the shell structure; fibers presented excellent mechanical stability | Drug delivery systems | [ |
| PLA; PCL | TCH | Bacteriostatic agent that inhibits protein synthesis; effective antibacterial agent. | Core-shell | Core: PCL (10% | The composition of the shell influenced the initial burst release, by working as a diffusion barrier | Drug delivery systems | [ |
| PCL; PGS | Heparin | Polyanionic polysaccharide; works as an anticoagulant. | Core-shell | Core: PGS (0/40/60/80% | Slow degradation of PCL provided the fibers with structural integrity, whereas fast degradation of PGS increased their elasticity; addition of PGS and grafting of heparin enhanced the attachment and proliferation of human umbilical vein endothelial cells | Tissue engineering scaffolds | [ |
| PCL | ShHL | Derived from | Core-shell | Core: PCL (10% | The increase of ShHL content led to higher ultimate tensile strengths; fibers showed high potential in decreasing neointimal proliferation and thrombogenicity of grafts and prosthesis | Tissue engineering scaffolds; blood-contacting devices | [ |
| PCL; PLGA; GN | RhB; FITC | FITC is a derivative of fluorescein, used for flow cytometry detection. | Tri-axial | Core: PCL 1% | The addition of PCL increased the fibers elastic modulus; fibers showed ideal support for the growth of mesenchymal stem cells | Regenerative engineering and drug delivery systems | [ |
| CA; PVP | KET | Nonsteroidal anti-inflammatory drug, used to treat pain and/or inflammation cause by arthritis. | Tri-axial | Core: CA/KET, injected at 0.0167 mL/min; | Fibers presented good dual drug release, with more accurate release contents at the initial stage and more prolonged sustained release at the second stage | Drug delivery systems | [ |
| PLA; PCL | DOX | Chemotherapy medication. | Porous | PLA and PCL were dissolved in DCM/DMF (98:2) in ratios of 3/1, 1/1 and 1/3, with a total polymer concentration of 8% | Fiber membranes promoted cutaneous wound healing, along with enhanced mechanical support and controlled release of therapeutic copper ions | Drug delivery systems; wound healing | [ |
| PCL | CAM | Antibiotic used to treat eye infections. | Porous | CAM (4% | Drug release from porous microfibers was facilitated; changes in humidity allows for fiber structure to be tuned and, consequently, the drug release profile | Drug delivery systems | [ |
| PLLA | - | - | Porous | PLLA (8% | 3D mats were formed with porous fibers and the addition of SLES surfactant led to higher crystallinity degree and enhanced cell proliferation | Tissue engineering scaffolds | [ |
| SF; PLLA | - | - | Side-by-side | Side 1: SF (10% | Results showed a dependence of the molecular orientation and secondary structure of the fibers on the alignment and annealing conditions; fibers treated with methanol and heated at 80 ºC revealed enhanced mechanical features | Medicine regenerative scaffolds; drug delivery systems | [ |
| PVP; PAN | DXM; 1,8-naphthalene anhydride; PMI | DXM is a corticosteroid, similar to natural hormones produced by adrenal glands; PMI is an anhydride diester, that can also be used as an intermediate for the synthesis of perylene carboxylic derivatives. | Side-by-side | Side 1: PVP (15% | Self-supporting properties were exhibited when PVP was dissolved in water; ideal biphasic drug release profiles were attained | Biphasic drug release | [ |
| PVP; EC | KET | Nonsteroidal anti-inflammatory drug, used to treat pain and/or inflammation cause by arthritis. | Side-by-side | Side 1: PVP (8% w(v) and KET (2% | PVP dissolved very rapidly and delivered a loading dose of ketoprofen, whereas EC released ketoprofen in a more sustained way; when PVP was added to EC, the second stage of release was accelerated | Drug delivery systems | [ |
| Alginate; PCL; PEO | ZnO NPs; Triton X-100 | Triton X-100 is a common nonionic surfactant, with conductive and dissipative properties. | Multilayered | Layer 1: PCL (10/20/30% | PCL provided good mechanical properties to the membrane, and worked as a protection from the external environment; alginate internal layer promoted cell viability, removed exudates, and allowed gas exchanges; ZnO NPs was antibacterial and bacteriostatic | Skin wound patch | [ |
| PCL; PLGA | RhB | RhB is an organic compound and a dye, used within water to determine direction flow. | Multilayered | Layer 1: PCL (10% | A prolonged release was achieved; FE and computational models could both provide accurate predictions of drug release | Prolonged drug delivery systems | [ |
| PLLA | - | - | Multilayered | Layer 1: PLLA (7.5% | Multilayer structures presented higher tensile strengths and favored the colonization and migration of H9C2 cells | Tissue regeneration scaffolding systems | [ |
| PCL; mGLT | - | - | Multilayered | Layer 1: PCL particles were dissolved in 18% | mGLT uniform distribution was attained and the scaffold maintained its mechanical strength; photocrosslinking allowed to form multilayered constructs, mimicking the structure of native tendon tissues | Tissue and ligament regeneration | [ |
Abbreviations: PU—polyurethane; HA—hyaluronic acid; St—starch; DMF—N,N-dimethylformamide; PCL—polycaprolactone; PEG—polyethylene glycol; AgNPs—silver nanoparticles; ZnO NPs—zinc oxide nanoparticles; CHF—chloroform; G—gauge; PLA—poly-lactic acid; TCH—tetracycline hydrochloride; PGS—poly(glycerol sebacate); TFE—trifluoroethanol; ShHL—sulfated hydrolyzed Halomonas; THF—tetrahydrofuran; DOX—doxorubicin; DCM—dichloromethane; CuS NPs—copper sulfide nanoparticles; CAM—chloramphenicol; DMSO—dimethyl sulfoxide; PLLA—poly(L-lactide); SLES—sodium lauryl ether sulfate; SF—silk fibroin; HFIP—hexafluoroisopropanol; PVP—polyvinylpyrrolidone; PAN—polyacrylonitrile; DXM—dexamethasone; PMI—perylene monoanhydride; EC—ethyl cellulose; KET—ketoprofen; PEO—poly(ethylene oxide); GAA—glacial acetic acid; Ac—acetone; PLGA—poly(d,l-lactic-co-glycolic acid); RhB—Rhodamine B; FE—computational finite element; TFE—2,2,2-trifluoroethanol; mGLT—methacrylated gelatin; GN—gelatin; FITC—fluorescein isothiocynate; HFP—1,1,1,3,3,3 hexafluoro-2-propanol; CA—cellulose acetate; PVP—polyvinylpyrrolidone; KET—ketoprofen.
Figure 6Schematic representation of the wet-spinning apparatus.
Figure 7Schematic representation of the most common wet-spun fibers structural organizations.
Figure 8SEM micrographs of (a) core-shell and (b) tri-axial wet-spun fibers (adapted with permission from [145], published by Wiley, 2015 and adapted from [146], published by MDPI, 2020).
Figure 9SEM micrographs of helical wet-spun fibers (adapted from [21], published by Beilstein-Institut Zur Forderung der Chemischen Wissenschaften, 2020).
Main applications of wet-spun fibers with various structural organizations and respective solution/processing parameters.
| Active Agents | |||||||
|---|---|---|---|---|---|---|---|
| Polymers | Name | Characteristics | Structural | Solution and Processing Parameters | Major Findings | Envisaged Applications | Ref. |
| PLA; PLGA; Alg | Mouse myoblasts | Cells that originate mouse muscle cells | Monolayer | Alg (2/4% | Improved in vitro proliferation; exceptional migration of cells; superior engraftment of donor cells | Regenerative skeletal muscle tissue constructs | [ |
| CA; PCL | Cinnamon leaf oil, Clove oil and Cajeput oil | Essential oils derived from steam distillation of plant leaves | Monolayer | CA (10% | Essential oil-loaded fibers eliminated bacteria more quickly than conventional antibiotics, proving their effective potential to replace antibiotics | Drug delivery systems (i.e., essential oils) | [ |
| SA/FK | IDM | Non-steroid anti-inflammatory used to relieve pain, swelling and joint stiffness caused by arthritis | Monolayer | FK (0.4/0.5/0.67% | IDM release profile increases over time, relieving the gastrointestinal system from side effects | Drug delivery system to relieve the gastrointestinal side reaction of indomethacin | [ |
| SA; GN | Nisin Z | Antimicrobial peptide, originated by the substitution of asparagine for histidine from Nisin A | Monolayer (uniaxial) | SA 2% | The incorporation of the peptide improved the fibers structural integrity and provided antibacterial effects against | Tissue engineering | [ |
| CHI | IONPs | IONPs display superparamagnetic properties, usually being presented as magnetite or in its oxidized maghemite form | Helical | IONPs (10% | IONPs were distributed in the fiber matrix as large clusters; dried CHI helices presented spring-like elastic behavior; fibers had strong ferromagnetic properties and exhibited a Young’s modulus in the range of wet-spun CHI fibers | Magnetic and motion-activated cell scaffolds | [ |
| CHI-PSS; CHI-PAA/PVS | - | - | Core-shell | Core: CHI (1.5/1.0% | Fibers mechanical properties were improved by doping PSS with PEO; fibers presented excellent elongation at break | Tissue engineering scaffolds | [ |
| PSU | - | - | Core-shell | Core: egg albumen was separated from the eggs and extruded at 0.367 mL/min; | A dense structure was obtained in the hollow space of the PSU fiber; the albumen fiber presented good gloss and mechanical properties | Tissue engineering scaffolds | [ |
| CHI; Alg | - | - | Core-shell | Core: CHI (0.5/1.0/2.0% | The incorporation of CaCl2 at the fiber’s core enhanced the mechanical properties by 260%; cylinder-shaped monofilaments of chitosan coated with alginate were successfully observed | Drug delivery systems | [ |
| HA; SH | IONPs; octenidine dihydrochloride | Octenidine dihydrochloride is a cationic surfactant, active against bacteria | Core-shell | Core: SH was dissolved in water; | Drug release from the core occurred through cracks; this rupture effect has can be used as a trigger release | Drug carrier | [ |
| PLGA; Alg | Dexamethasone; dexamethasone-21-phosphate | Corticosteroid, similar to a natural hormone produced by your adrenal glands; dexamethasone 21-phosphate works as an inducer of apoptosis and inhibitor of the sodium phosphate symporter | Core-shell | Core: PLGA (20% | Alg shell delayed dexamethasone release; the core-shell structure presented two stage releases of dexamethasone and dexamethasone-21-phosphate, with minimum initial burst release | Dual drug delivery system | [ |
Abbreviations: PLA—poly(lactic) acid; PLGA—poly(lactide-co-glycolide); Alg—alginate; CaCl2—calcium chloride; CA—cellulose acetate; PCL—polycaprolactone; SA—sodium alginate; FK—feather keratin; IDM—indomethacin; NaOH—sodium hydroxide; GN—gelatin; CHI—chitosan; IONPs—iron oxide nanoparticles; PSS—polystyrene sulfonate; PAA—poly(acrylic acid); PVS—poly(vinyl sulfate); PEO—poly(ethylene oxide); PSU—polysulfone; DMF—N,N-dimethylformamide; HA—hyaluronic acid; SH—sodium hyaluronate; DMSO—dimethylsulfoxide.